Last reviewed 2026-04-23 · How we verify

Diclofenac Test (lower dose)

Iroko Pharmaceuticals, LLC · Phase 3 active Small molecule

Diclofenac Test (lower dose) is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Iroko Pharmaceuticals, LLC. It is currently in Phase 3 development for Acute pain management (Phase 3 evaluation at lower dose), Osteoarthritis or rheumatoid arthritis (potential indication).

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain.

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain. Used for Acute pain management (Phase 3 evaluation at lower dose), Osteoarthritis or rheumatoid arthritis (potential indication).

Likelihood of approval

59.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Diclofenac Test (lower dose)
Sponsor	Iroko Pharmaceuticals, LLC
Drug class	Nonsteroidal anti-inflammatory drug (NSAID)
Target	COX-1 and COX-2
Modality	Small molecule
Therapeutic area	Pain Management / Rheumatology
Phase	Phase 3

Mechanism of action

Diclofenac blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin levels, diclofenac provides analgesic and anti-inflammatory effects. The lower-dose formulation in this Phase 3 trial is being evaluated to optimize efficacy while potentially reducing gastrointestinal and cardiovascular risks associated with standard NSAID dosing.

Approved indications

Acute pain management (Phase 3 evaluation at lower dose)
Osteoarthritis or rheumatoid arthritis (potential indication)

Common side effects

Gastrointestinal upset / dyspepsia
Abdominal pain
Nausea
Headache
Dizziness
Increased cardiovascular risk (with chronic use)

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Diclofenac Test (lower dose) CI brief — competitive landscape report
Diclofenac Test (lower dose) updates RSS · CI watch RSS
Iroko Pharmaceuticals, LLC portfolio CI

Frequently asked questions about Diclofenac Test (lower dose)

What is Diclofenac Test (lower dose)?

Diclofenac Test (lower dose) is a Nonsteroidal anti-inflammatory drug (NSAID) drug developed by Iroko Pharmaceuticals, LLC, indicated for Acute pain management (Phase 3 evaluation at lower dose), Osteoarthritis or rheumatoid arthritis (potential indication).

How does Diclofenac Test (lower dose) work?

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain.

What is Diclofenac Test (lower dose) used for?

Diclofenac Test (lower dose) is indicated for Acute pain management (Phase 3 evaluation at lower dose), Osteoarthritis or rheumatoid arthritis (potential indication).

Who makes Diclofenac Test (lower dose)?

Diclofenac Test (lower dose) is developed by Iroko Pharmaceuticals, LLC (see full Iroko Pharmaceuticals, LLC pipeline at /company/iroko-pharmaceuticals-llc).

What drug class is Diclofenac Test (lower dose) in?

Diclofenac Test (lower dose) belongs to the Nonsteroidal anti-inflammatory drug (NSAID) class. See all Nonsteroidal anti-inflammatory drug (NSAID) drugs at /class/nonsteroidal-anti-inflammatory-drug-nsaid.

What development phase is Diclofenac Test (lower dose) in?

Diclofenac Test (lower dose) is in Phase 3.

What are the side effects of Diclofenac Test (lower dose)?

Common side effects of Diclofenac Test (lower dose) include Gastrointestinal upset / dyspepsia, Abdominal pain, Nausea, Headache, Dizziness, Increased cardiovascular risk (with chronic use).

What does Diclofenac Test (lower dose) target?

Diclofenac Test (lower dose) targets COX-1 and COX-2 and is a Nonsteroidal anti-inflammatory drug (NSAID).

Drug class: All Nonsteroidal anti-inflammatory drug (NSAID) drugs
Target: All drugs targeting COX-1 and COX-2
Manufacturer: Iroko Pharmaceuticals, LLC — full pipeline
Therapeutic area: All drugs in Pain Management / Rheumatology
Indication: Drugs for Acute pain management (Phase 3 evaluation at lower dose)
Indication: Drugs for Osteoarthritis or rheumatoid arthritis (potential indication)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing